Background: It is occasionally difficult to diagnose cT3 or cT4b using imaging examinations for esophageal cancer. The optimal treatment strategy for borderline resectable esophageal squamous cell carcinoma (BR-ESCC) is unclear.
Methods: We included 131 patients with cT3 ESCC who received neoadjuvant chemoradiotherapy (NCRT) followed by surgery. The patients were classified as having definitive cT3 (D-cT3) or borderline resectable cT3 (BR-cT3), based on presence of undeniable adjacent organ invasion on pretreatment CT. Surgical outcomes and prognoses were compared among patients with D-cT3 and BR-cT3 tumors, and the risk factors for non-R0 resection were assessed.
Results: Ninety and 41 patients were classified as D-cT3 and BR-cT3, respectively. Although BR-cT3 had a significantly higher non-R0 resection rate than D-cT3 (D-cT3 3.7%; BR-cT3 14.6%), BR-cT3 was not correlated with shorter overall survival (OS) (D-cT3 5-year OS, 50.8%; BR-cT3 5-year OS 38.4%; p = 0.234). Conversely, non-R0 resection was significantly associated with poor OS (R0 resection 5-year OS 48.8%; non-R0 resection 5-year OS 22.2%; p = 0.031). Cox regression analysis of OS demonstrated that BR-cT3 was not a prognostic factor. In the analysis of risk factors for non-R0 resection, BR-cT3 (p = 0.027), suspected invasion of the trachea or bronchus (p = 0.046), and high SUVmax of the primary lesion after NCRT (p = 0.002) were risk factors.
Conclusions: NCRT followed by surgery achieved a relatively high R0 resection rate and an almost equal overall survival rate for BR-cT3 compared with D-cT3 ESCC. Thus, NCRT followed by surgery is an effective treatment strategy for patients with BR-cT3 ESCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00268-022-06568-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resection.
Oncol Lett
January 2025
Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan, R.O.C.
Article Synopsis
- * Key factors associated with worse progression-free survival (PFS) included driver gene mutations, being classified as Eastern Cooperative Oncology Group performance status 2, and having stage II-IIIB tumors.
- * Despite the increased risk of disease progression linked to driver gene mutations, those receiving driver gene-targeted therapy showed improved post-progression survival rates, suggesting that early testing for these mutations could be beneficial in treatment planning.
Single-center clinical experience of extended sleeve lobectomy (ESL) versus standard sleeve lobectomy (SL).
Transl Lung Cancer Res
August 2024
Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China.
Background: Sleeve lobectomy (SL) and extended SL (ESL), which aim to preserve pulmonary function and enhance the quality of life of patients while ensuring oncological outcomes, are valuable surgical options for the treatment of centrally located non-small cell lung cancer (NSCLC). This study aimed to compare perioperative adverse events and long-term survival between SL and ESL in NSCLC patients, providing a comprehensive review of surgical outcomes, complications, and survival to assess the roles of SL and ESL in thoracic oncology.
Methods: This single-center retrospective study assessed the outcomes of NSCLC patients who underwent SL or ESL from June 2014 to January 2022.
Impact of longitudinal tumor location on postoperative outcomes in gallbladder cancer: Fundus and body vs. neck and cystic duct, a retrospective multicenter study.
Ann Hepatobiliary Pancreat Surg
November 2024
Department of Surgery, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
Article Synopsis
- - The study aimed to investigate how the location of gallbladder cancer (GBC) tumors affects patient outcomes, as previous research was limited and inconclusive.
- - Researchers conducted a multicenter analysis of 372 patients who underwent surgery for GBC, categorizing them into two groups: those with tumors in the fundus/body (FB-GBC) and those in the neck/cystic duct (NC-GBC).
- - Results indicated that NC-GBC patients experienced worse outcomes, including more advanced cancer stages, lower rates of successful tumor removal (R0), and higher recurrence and mortality rates, yet the specific location of the tumor was not identified as an independent factor influencing prognosis.
Risk factor analysis and nomogram construction of postoperative complications for patients with locally advanced gastric cancer who received neoadjuvant immunotherapy and chemotherapy.
Front Med (Lausanne)
July 2024
School of Medicine, Nankai University, Tianjin, China.
Introduction: The combination of neoadjuvant immunotherapy and chemotherapy (NICT) has become a common treatment regimen for locally advanced gastric cancer (LAGC). However, the safety and efficacy of radical gastrectomy following NICT (NICT-G) remain controversial. This study aimed to analyze the risk factors influencing postoperative complications (POCs) after NICT-G.
View Article and Find Full Text PDFClinicopathological spectrum, management, and outcome of ectopic parathyroid carcinoma: Experience with 24 cases.
Endocrine
November 2024
Department of Thyroid and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Purpose: Ectopic parathyroid carcinoma (EPC) is a rare clinical entity with multiple diagnostic pitfalls, making surgical cures challenging. We assessed the clinicopathological spectrum and outcome of EPCs.
Methods: In this retrospective cohort study, 24 EPCs were identified from 133 PC patients treated at a tertiary referral center.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!